Chemotherapy News and Research

Latest Chemotherapy News and Research

PCFT helps in effectively targeting cytotoxic antifolates to tumors: Study

Scientists at the Barbara Ann Karmanos Cancer Institute in Detroit today presented a poster at the American Association for Cancer Research's 101st Annual Meeting 2010 that details their novel study of molecules that use a tumor's acidic microenvironment to help them tailor chemotherapeutic agents to kill the tumor.

23 Apr 2010

Geron scientists highlight importance of telomerase inhibitor, GRN163L at AACR 2010

Geron Corporation today announced five presentations by Geron scientists and collaborators on the company's telomerase inhibitor, imetelstat sodium, including the drug's activity against cancer stem cells, at the 101st American Association for Cancer Research annual meeting held in Washington D.C.

23 Apr 2010

Genentech submits sBLA for Herceptin plus chemotherapy for advanced HER2-positive stomach cancer

Genentech, Inc., a wholly owned member of the Roche Group, announced today that the company submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Herceptin® (trastuzumab) plus chemotherapy in people with advanced, HER2-positive adenocarcinoma of the stomach, including gastroesophageal junction cancer.

23 Apr 2010

Waxman Foundation honors molecular biologist Alan Ashworth with the David T. Workman Memorial Award

Molecular biologist Alan Ashworth, Ph.D., FRS, the director of the Breakthrough Breast Cancer Research Centre at the Institute of Cancer Research in London will receive the David T. Workman Memorial Award on May 17. The two-year grant of $50,000 from the Samuel Waxman Cancer Research Foundation will support Dr. Ashworth's work with PARP inhibitors in BRCA-mutated cancers.

23 Apr 2010

BSD-2000 Hyperthermia System combined with chemotherapy promising for children with high-risk tumors

BSD Medical Corporation today reported clinical study data showing that hyperthermia, using the BSD-2000 Hyperthermia System, combined with chemotherapy has the potential to improve control rate and long-term survival for the treatment of children with high-risk cancer who have a dismal prognosis.

23 Apr 2010

RMEI, PIM jointly sponsor complimentary continuing education virtual lecture on CRPC

Castrate-refractory prostate cancer, which is characterized by tumor progression despite castrate levels of testosterone, develops in many prostate cancer patients treated with androgen-deprivation therapy. Standardized guidelines for the treatment of CRPC are lacking, and a number of factors must be considered when deciding between second-line hormonal therapy and chemotherapy.

23 Apr 2010

Data from pivotal study of Marqibo in ALL patients to be presented at ASCO meeting

Hana Biosciences, a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that complete data from its pivotal study of Marqibo in patients with relapsed/refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia, have been accepted for an oral podium presentation at the 46th Annual Meeting of the American Society of Clinical Oncology to be held June 4-8, 2010 in Chicago, Illinois.

23 Apr 2010

Acacia Research reports record first-quarter license fee revenues of $39.77M

Acacia Research Corporation today reported results for the three months ended March 31, 2010.

23 Apr 2010

International Day for Fighting Infection focuses on hospital infection control

Hospital acquired infections are the focus for the 3rd International Day for Fighting Infection, being marked on St. George’s Day, as experts meet to look at the evolution of infection control in hospitals.

22 Apr 2010

SGO white paper reviews current status of HPV typing, its benefits and deficiencies

The Society of Gynecologic Oncologists has published its second in a series of four papers on a variety of cervical cancer issues and topics that were the focus of its Forum "The Future Strategies for Cervical Cancer Prevention: What Do We Need to Do Now to Prepare."

22 Apr 2010

Positive results from preclinical EP-302 program presented at AACR 2010

Drug discovery and development company Esperance Pharmaceuticals today presented positive results from their preclinical EP-302 program that support the initiation of IND enabling studies. EP-302 is a targeted membrane-disrupting peptide designed to selectively kill cells that express nucleolin on their surface. Nucleolin is a protein that is over-expressed in a wide range of cancers and tumor endothelial cells.

22 Apr 2010

Manhattan Scientifics' early cancer detection technology offers better results than mammogram test

Manhattan Scientifics, Inc. announced today that its "early cancer detection" technology, developed by Edward R. Flynn, Ph.D. is expected to identify breast cancer three years earlier than the current gold standard mammogram test. Dr. Flynn is a pioneer in the emerging field of nano medicine.

22 Apr 2010

ImmunoCellular Therapeutics, UPENN sign research agreement

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today that the Company has entered into a sponsored research agreement and an option agreement with The University of Pennsylvania to support process development and manufacturing in a planned Phase II clinical trial of ICT-107, the Company's dendritic-cell based cancer vaccine product candidate for the treatment of glioblastoma multiforme.

22 Apr 2010

NPS Pharmaceuticals closes public offering of common stock shares

NPS Pharmaceuticals, Inc. today announced the closing of a public offering of 10,350,000 shares of its common stock, including 1,350,000 shares sold pursuant to the full exercise of an overallotment option previously granted to the underwriters. All of the shares were offered by the Company. Net proceeds were approximately $53.3 million after deducting underwriting discounts and commissions, and estimated offering expenses. Canaccord Adams acted as sole book-running manager and Needham & Company, LLC acted as co-manager for the offering.

22 Apr 2010

Infinity Pharmaceuticals initiates Phase 1b/2 trial of IPI-926 Hedgehog pathway inhibitor for pancreatic cancer

Infinity Pharmaceuticals, Inc., an innovative drug discovery and development company, today announced that it has initiated a randomized Phase 1b/2 clinical trial evaluating IPI-926, its novel, oral Hedgehog pathway inhibitor, in combination with gemcitabine in patients with pancreatic cancer.

22 Apr 2010

Delcath Systems' trial meets primary endpoint of extended hPFS in patients with melanoma metastases

Delcath Systems, Inc., a development stage, oncology-focused, specialty pharmaceutical and medical device company, announced that its Phase III National Cancer Institute (NCI)-led multi-center clinical trial has successfully met the study's primary endpoint of extended hepatic progression-free survival (hPFS) in patients with melanoma metastases to the liver based on an independently corroborated intent-to-treat analysis.

22 Apr 2010

Access Pharmaceuticals to present MuGard clinical data at 2010 MASCC conference

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company specializing in products for cancer and supportive care, announced today that it will present data from the ongoing work involving its lead product, MuGard, and host an oral mucositis symposium at the MASCC conference being held in Vancouver, B.C. on June 24-26, 2010. MuGard is Access Pharma's FDA-approved product for the management of oral mucositis, a debilitating side effect of many anticancer treatments.

22 Apr 2010

New method to analyze molecular activity of cancer drugs for solid tumors using skin biopsies

A research team today reported clinical results of a new method for analyzing the molecular activity of cancer drugs for solid tumors using skin biopsies. The approach, enabled by Cambridge Research & Instrumentation, Inc.'s imaging and analysis systems, was presented in a poster session at the American Association of Cancer Research's Annual Meeting in Washington D.C.

21 Apr 2010

Alchemia’s HyACT tumour targeting technology enhances killing of cancer stem cells

Alchemia's subsidiary Alchemia Oncology today presented two posters at the American Association of Cancer Research (AACR) 101st Annual Meeting in Washington, DC. The data demonstrates the ability of the Company's HyACT tumour targeting technology to dramatically enhance the killing of cancer stem cells. These cells are highly resistant to treatment with chemotherapeutic drugs and are believed to be responsible for treatment failure and disease recurrence.

21 Apr 2010

Preclinical data of ANG1005 and ANG1007 for treatment of brain cancer presented at AACR 2010

Angiochem, Inc., a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier through LRP-1 targeting, announced today that preclinical data was presented on two of its oncology programs, ANG1005 and ANG1007, for the treatment of brain cancers at the 101st Annual meeting of the American Association for Cancer Research 2010, April 17-21, in Washington, DC.

21 Apr 2010

Chemotherapy News and Research

Latest Chemotherapy News and Research

PCFT helps in effectively targeting cytotoxic antifolates to tumors: Study

Geron scientists highlight importance of telomerase inhibitor, GRN163L at AACR 2010

Genentech submits sBLA for Herceptin plus chemotherapy for advanced HER2-positive stomach cancer

Waxman Foundation honors molecular biologist Alan Ashworth with the David T. Workman Memorial Award

BSD-2000 Hyperthermia System combined with chemotherapy promising for children with high-risk tumors

RMEI, PIM jointly sponsor complimentary continuing education virtual lecture on CRPC

Data from pivotal study of Marqibo in ALL patients to be presented at ASCO meeting

Acacia Research reports record first-quarter license fee revenues of $39.77M

International Day for Fighting Infection focuses on hospital infection control

SGO white paper reviews current status of HPV typing, its benefits and deficiencies

Positive results from preclinical EP-302 program presented at AACR 2010

Manhattan Scientifics' early cancer detection technology offers better results than mammogram test

ImmunoCellular Therapeutics, UPENN sign research agreement

NPS Pharmaceuticals closes public offering of common stock shares

Infinity Pharmaceuticals initiates Phase 1b/2 trial of IPI-926 Hedgehog pathway inhibitor for pancreatic cancer

Delcath Systems' trial meets primary endpoint of extended hPFS in patients with melanoma metastases

Access Pharmaceuticals to present MuGard clinical data at 2010 MASCC conference

New method to analyze molecular activity of cancer drugs for solid tumors using skin biopsies

Alchemia’s HyACT tumour targeting technology enhances killing of cancer stem cells

Preclinical data of ANG1005 and ANG1007 for treatment of brain cancer presented at AACR 2010

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in